BNP Paribas Financial Markets’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-9,972
| Closed | -$179K | – | 4362 |
|
|
2020
Q2 | $179K | Sell |
9,972
-35,143
| -78% | -$489K | ﹤0.01% | 2539 |
|
|
2020
Q1 | $322K | Buy |
45,115
+27,829
| +161% | +$347K | ﹤0.01% | 2603 |
|
|
2019
Q4 | $413K | Buy |
17,286
+1,843
| +12% | +$50.8K | ﹤0.01% | 2572 |
|
|
2019
Q3 | $414K | Buy |
15,443
+3,027
| +24% | +$85K | ﹤0.01% | 2315 |
|
|
2019
Q2 | $337K | Sell |
12,416
-2,624
| -17% | -$82.3K | ﹤0.01% | 2263 |
|
|
2019
Q1 | $522K | Buy |
15,040
+11,736
| +355% | +$339K | ﹤0.01% | 2074 |
|
|
2018
Q4 | $64.5K | Sell |
3,304
-1,719
| -34% | -$35.4K | ﹤0.01% | 2593 |
|
|
2018
Q3 | $134K | Sell |
5,023
-152,173
| -97% | -$4.97M | ﹤0.01% | 2594 |
|
|
2018
Q2 | $5.94M | Buy |
157,196
+145,094
| +1,199% | +$5.55M | 0.01% | 1022 |
|
|
2018
Q1 | $395K | Buy |
12,102
+33
| +0.3% | +$1.45K | ﹤0.01% | 2366 |
|
|
2017
Q4 | $588K | Buy |
12,069
+5,191
| +75% | +$263K | ﹤0.01% | 2358 |
|
|
2017
Q3 | $372K | Buy |
6,878
+469
| +7% | +$27.5K | ﹤0.01% | 2132 |
|
|
2017
Q2 | $360K | Buy |
6,409
+5,278
| +467% | +$211K | ﹤0.01% | 2101 |
|
|
2017
Q1 | $44.3K | Sell |
1,131
-665
| -37% | -$21.2K | ﹤0.01% | 2781 |
|
|
2016
Q4 | $40.3K | Sell |
1,796
-2,350
| -57% | -$45.9K | ﹤0.01% | 2928 |
|
|
2016
Q3 | $94.2K | Buy |
4,146
+2,192
| +112% | +$51.5K | ﹤0.01% | 2131 |
|
|
2016
Q2 | $46.1K | Buy |
1,954
+1,914
| +4,785% | +$47.3K | ﹤0.01% | 2324 |
|
|
2016
Q1 | $816 | Sell |
40
-76,812
| -100% | -$2.44M | ﹤0.01% | 2525 |
|
|
2015
Q4 | $3.95M | Buy |
76,852
+34,140
| +80% | +$1.66M | 0.01% | 712 |
|
|
2015
Q3 | $1.82M | Buy |
42,712
+5,568
| +15% | +$269K | ﹤0.01% | 879 |
|
|
2015
Q2 | $1.69M | Buy |
37,144
+36,125
| +3,545% | +$1.45M | ﹤0.01% | 932 |
|
|
2015
Q1 | $38.7K | Buy |
+1,019
| New | +$35K | ﹤0.01% | 2048 |
|
|
2014
Q4 | – | Sell |
-2,189
| Closed | -$55.3K | – | 3545 |
|
|
2014
Q3 | $55.3K | Buy |
2,189
+2,130
| +3,610% | +$56.1K | ﹤0.01% | 2535 |
|
|
2014
Q2 | $1.72K | Buy |
+59
| New | +$1.43K | ﹤0.01% | 3196 |
|
|
2014
Q1 | – | Sell |
-141
| Closed | -$3.63K | – | 3962 |
|
|
2013
Q4 | $3.63K | Buy |
+141
| New | +$3.43K | ﹤0.01% | 3306 |
|
BNP Paribas Financial Markets's PTLA Position: Q3 2020 in Review
BNP Paribas Financial Markets sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 9,972 shares — an estimated $179K sold.
BNP Paribas Financial Markets first reported a position in PTLA in Q4 2013 and held it in 25 quarters. The position peaked at $5.94M in Q2 2018. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- BNP Paribas Financial Markets reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- BNP Paribas Financial Markets sold 9,972 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $179K.
- BNP Paribas Financial Markets first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 25 quarters.
- BNP Paribas Financial Markets's Portola Pharmaceuticals, Inc. position peaked at $5.94M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2020, filed 30 Oct 2020.